Developer docs
API playgroundTry for free, no card

Search company profiles

Modag

Full company profile

uuid0002oe6

Namestring
Modag
Legal namestring
MODAG GmbH
Websiteurl
modag.net
Company typeenum
Private
Founded yearint
2013
Descriptiontext

MODAG GmbH is a privately held German biotechnology company founded in 2013 and headquartered in Wendelsheim, Rhineland-Palatinate, with 11-50 employees. The company develops disease-modifying small-molecule therapeutics and molecular diagnostics targeting pathological alpha-synuclein aggregates in neurodegenerative diseases, primarily Multiple System Atrophy (MSA) and Parkinson's disease.

The company's pipeline is anchored by Emrusolmin (anle138b/TEV-56286), an orally bioavailable oligomer modulator that binds and dissolves toxic alpha-synuclein oligomers and crosses the blood-brain barrier; the compound has completed Phase 1 studies with favorable safety and is currently in a 200-participant Phase 2 trial for MSA, and has received both FDA Orphan Drug (2022) and Fast Track (September 2025) designations. MODAG also markets PD DETECT, the world's first CE-certified (IVDR) biochemical standardized test kit for Parkinson's disease, which detects alpha-synuclein aggregates in cerebrospinal fluid with 97.8% sensitivity and 100% specificity, and is developing a PET tracer program for molecular imaging of synucleinopathies in collaboration with the University of Tübingen, Max Planck Institute, and LMU Munich.

MODAG operates a hybrid revenue model combining licensing and collaboration revenue (exclusive worldwide partnership with Teva Pharmaceutical Industries for Emrusolmin and Sery433, generating upfront payments, development milestones, and royalties), direct diagnostic product sales (PD DETECT) to specialized diagnostic laboratories, university clinics, and research institutions, and non-dilutive research grants (notably $1.4M and $1M awards from The Michael J. Fox Foundation). The company outsources global therapeutic commercialization to Teva while maintaining a focused direct-sales motion for its diagnostic franchise in the DACH region and beyond.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWendelsheim, Germany
HQ citystring
Wendelsheim
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurodegenerative disease therapeutics, oligomer modulator drugs, alpha-synuclein therapeutics, Parkinson disease diagnostics, biopharmaceutical small molecules
Industry3 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceuticals and Diagnostics for Neurodegenerative Diseases
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Products
TypeOthers
Description

MODAG generates revenue through sale of diagnostic test kits (PD DETECT) to specialized diagnostic laboratories, university clinics, and research institutions.

modag.net
2Licensing and Collaboration Revenue
TypeLicensing Royalties
Description

Exclusive worldwide licensing and development collaboration with Teva Pharmaceutical for Anle138b (Emrusolmin) and Sery433. MODAG receives upfront payments, development milestones, and royalties on commercial sales from this partnership.

modag.net
3Research Grants
TypeProfessional Services
Description

Funding from The Michael J. Fox Foundation ($1 million grant) and other organizations supporting PET tracer development and clinical research.

modag.net
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1PD DETECT
Description

World's first CE-certified biochemical standardized test kit for Parkinson's disease, detecting abnormal alpha-synuclein protein aggregates in cerebrospinal fluid

modag.net
+1 more record
Core offering1 text field

MODAG develops and commercializes disease-modifying small-molecule therapeutics (Emrusolmin/anle138b) and companion biochemical diagnostics (PD DETECT) targeting pathological alpha-synuclein aggregates in neurodegenerative diseases, specifically Parkinson's disease and Multiple System Atrophy (MSA). The company combines proprietary oligomer modulator chemistry with the world's first CE-IVDR-certified seed amplification assay for Parkinson's diagnosis and is developing PET tracers for molecular imaging of synucleinopathies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • PD DETECT sensitivity: 97.8%
+2 more records
Product overview1 text field

MODAG develops a portfolio of therapeutic and diagnostic products for neurodegenerative diseases, centered on two main offerings: Emrusolmin (anle138b/TEV-56286), a disease-modifying small-molecule therapeutic targeting alpha-synuclein oligomers for MSA and Parkinson's disease, and PD DETECT, the world's first CE-certified diagnostic test kit for Parkinson's disease detection via alpha-synuclein seed amplification assay in cerebrospinal fluid. The company also develops PET tracer candidates for molecular imaging of synucleinopathies. This combination of targeted therapeutics and molecular diagnostics represents an integrated approach to addressing neurodegenerative diseases.

Product and service3 records
1PD DETECT
CategoryDiagnostic product
Description

The world's first CE-IVDR-certified biochemical standardized test kit for Parkinson's disease, designed to detect abnormal alpha-synuclein protein aggregates in cerebrospinal fluid using seed amplification assay (SAA) technology. Delivers 97.8% sensitivity and 100% specificity, enabling earlier and more objective diagnosis by identifying underlying biology before motor symptoms fully manifest. Made available to specialized diagnostic laboratories, university clinics, and research institutions.

2Emrusolmin (anle138b / TEV-56286)
CategoryTherapeutic product
Description

A low-molecular-weight drug candidate (oligomer modulator) that specifically binds to toxic oligomer structures of alpha-synuclein, dissolves toxic oligomers, and prevents formation of new oligomers. Can be administered orally and efficiently crosses the blood-brain barrier to act directly intracellularly on toxic oligomers. Developed for Multiple System Atrophy (MSA) and Parkinson's disease in partnership with Teva Pharmaceutical, with FDA Fast Track and Orphan Drug Designations. Currently in Phase 2 clinical study with 200 study participants.

3PET Tracer Program
CategoryDiagnostic imaging product
Description

Novel PET tracer compounds that specifically target aggregated alpha-synuclein, enabling direct molecular imaging and quantification of alpha-synuclein deposits in patients' brains for the first time. First tracer candidates have been explored in human PET images in patients with MSA and Parkinson's disease, showing promising preliminary results. Developed in collaboration with University of Tübingen, Max Planck Institute for Multidisciplinary Sciences, and LMU Munich.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-26
Description

Exclusive worldwide licensing and development collaboration for Anle138b (Emrusolmin) and Sery433. Teva received exclusive rights to develop, manufacture, and commercialize these compounds. Both companies jointly develop the drugs for MSA and Parkinson's disease indications, with potential for additional indications based on clinical outcomes. The partnership leverages Teva's neuroscience expertise and global commercial infrastructure.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Academic partner in PET tracer program development, contributing to molecular imaging research for synucleinopathies.

3Max Planck Institute for Multidisciplinary Sciences, Göttingen
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Academic research partner contributing to PET tracer development and alpha-synuclein research. Foundation partner in company's scientific origins.

modag.net
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Academic partner in PET tracer research and fundamental research origin of MODAG's technology platform. Company was founded based on discoveries from LMU scientists.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Contract research organization that conducted the Phase 1b study for anle138b in Parkinson's patients in collaboration with University Hospital Nottingham.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Prothena, partnered with Roche, is developing prasinezumab, a monoclonal antibody targeting aggregated alpha-synuclein for Parkinson's disease. It is the most direct mechanistic competitor to MODAG's Emrusolmin in the synucleinopathy space.

TypeBroad incumbent
Description

Biogen developed cinpanemab, an alpha-synuclein antibody for Parkinson's, and has a broad neuroscience portfolio. As a large CNS player pursuing the same target, Biogen is a direct mechanistic and indication peer even though MODAG is far smaller.

TypeDirect peer
Description

AC Immune is a clinical-stage Swiss biotech developing alpha-synuclein-targeted therapeutics and diagnostics for Parkinson's and related synucleinopathies. It is closely comparable as a European, CNS-focused, alpha-synuclein platform company.

TypeEmerging player
Description

Denali is a clinical-stage neurodegeneration biotech developing small molecules and biologics for Parkinson's and related diseases, including programs that intersect with alpha-synuclein biology. It is a peer in CNS drug development with broader neurodegeneration scope.

TypeEmerging player
Description

BioArctic is a Swedish biotech developing alpha-synuclein PET tracers and antibody-based therapies for Parkinson's disease. The PET tracer program is a direct peer to MODAG's PET tracer initiative, while their antibody work is mechanistically adjacent.

TypeBroad incumbent
Description

Lundbeck is a Denmark-based specialty pharmaceutical company focused on CNS disorders including Parkinson's disease. It competes for the same patient population and physician channels that MODAG's therapeutic and diagnostic programs target.

TypeDirect peer
Description

Amprion develops SYNTap, a seed amplification assay for misfolded alpha-synuclein used in Parkinson's diagnosis and clinical research. It is a direct competitor to MODAG's PD DETECT diagnostic kit and is widely used in academic and pharma studies.

TypeBroad incumbent
Description

UCB is a global biopharma company with a growing neuroscience portfolio including Parkinson's disease programs. It is comparable as a CNS-focused commercial-stage peer whose indication overlap puts it in direct competition for future launch slots.

TypeEmerging player
Description

Cerevel, now part of AbbVie, is developing CNS therapeutics including assets for Parkinson's disease. It is an emerging peer in the disease-modifying Parkinson's space, with similar neuroscience specialization to MODAG's therapeutic ambition.

TypeOthers
Description

Quotient Sciences is the contract research organization that conducted MODAG's Phase 1b anle138b study in Parkinson's patients. It is an enabling/operational peer in MODAG's drug development workflow rather than a direct competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Modag

Biopharmaceuticals and Diagnostics for Neurodegenerative Diseasesmodag.net

What Modag does

MODAG GmbH is a privately held German biotechnology company founded in 2013 and headquartered in Wendelsheim, Rhineland-Palatinate, with 11-50 employees. The company develops disease-modifying small-molecule therapeutics and molecular diagnostics targeting pathological alpha-synuclein aggregates in neurodegenerative diseases, primarily Multiple System Atrophy (MSA) and Parkinson's disease.

The company's pipeline is anchored by Emrusolmin (anle138b/TEV-56286), an orally bioavailable oligomer modulator that binds and dissolves toxic alpha-synuclein oligomers and crosses the blood-brain barrier; the compound has completed Phase 1 studies with favorable safety and is currently in a 200-participant Phase 2 trial for MSA, and has received both FDA Orphan Drug (2022) and Fast Track (September 2025) designations. MODAG also markets PD DETECT, the world's first CE-certified (IVDR) biochemical standardized test kit for Parkinson's disease, which detects alpha-synuclein aggregates in cerebrospinal fluid with 97.8% sensitivity and 100% specificity, and is developing a PET tracer program for molecular imaging of synucleinopathies in collaboration with the University of Tübingen, Max Planck Institute, and LMU Munich.

MODAG operates a hybrid revenue model combining licensing and collaboration revenue (exclusive worldwide partnership with Teva Pharmaceutical Industries for Emrusolmin and Sery433, generating upfront payments, development milestones, and royalties), direct diagnostic product sales (PD DETECT) to specialized diagnostic laboratories, university clinics, and research institutions, and non-dilutive research grants (notably $1.4M and $1M awards from The Michael J. Fox Foundation). The company outsources global therapeutic commercialization to Teva while maintaining a focused direct-sales motion for its diagnostic franchise in the DACH region and beyond.

Modag firmographics

Firmographics
Name
Modag
Legal name
MODAG GmbH
Website
https://modag.net
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Modag industry classification

Industry
Product category
Biopharmaceuticals and Diagnostics for Neurodegenerative Diseases
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Neurodegenerative disease therapeutics
  • Oligomer modulator drugs
  • Alpha-synuclein therapeutics
  • Parkinson disease diagnostics
  • Biopharmaceutical small molecules

Where Modag is headquartered

Location

Headquarters

HQ city
Wendelsheim
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Modag business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Diagnostic Products: MODAG generates revenue through sale of diagnostic test kits (PD DETECT) to specialized diagnostic laboratories, university clinics, and research institutions.
  2. Licensing and Collaboration Revenue: Exclusive worldwide licensing and development collaboration with Teva Pharmaceutical for Anle138b (Emrusolmin) and Sery433. MODAG receives upfront payments, development milestones, and royalties on commercial sales from this partnership.
  3. Research Grants: Funding from The Michael J. Fox Foundation ($1 million grant) and other organizations supporting PET tracer development and clinical research.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Modag product offering

Product offering

Core offering

MODAG develops and commercializes disease-modifying small-molecule therapeutics (Emrusolmin/anle138b) and companion biochemical diagnostics (PD DETECT) targeting pathological alpha-synuclein aggregates in neurodegenerative diseases, specifically Parkinson's disease and Multiple System Atrophy (MSA). The company combines proprietary oligomer modulator chemistry with the world's first CE-IVDR-certified seed amplification assay for Parkinson's diagnosis and is developing PET tracers for molecular imaging of synucleinopathies.

Product overview

MODAG develops a portfolio of therapeutic and diagnostic products for neurodegenerative diseases, centered on two main offerings: Emrusolmin (anle138b/TEV-56286), a disease-modifying small-molecule therapeutic targeting alpha-synuclein oligomers for MSA and Parkinson's disease, and PD DETECT, the world's first CE-certified diagnostic test kit for Parkinson's disease detection via alpha-synuclein seed amplification assay in cerebrospinal fluid. The company also develops PET tracer candidates for molecular imaging of synucleinopathies. This combination of targeted therapeutics and molecular diagnostics represents an integrated approach to addressing neurodegenerative diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • PD DETECT: World's first CE-certified biochemical standardized test kit for Parkinson's disease, detecting abnormal alpha-synuclein protein aggregates in cerebrospinal fluid
  • Emrusolmin

Products and services

  • PD DETECT The world's first CE-IVDR-certified biochemical standardized test kit for Parkinson's disease, designed to detect abnormal alpha-synuclein protein aggregates in cerebrospinal fluid using seed amplification assay (SAA) technology. Delivers 97.8% sensitivity and 100% specificity, enabling earlier and more objective diagnosis by identifying underlying biology before motor symptoms fully manifest. Made available to specialized diagnostic laboratories, university clinics, and research institutions.
  • Emrusolmin (anle138b / TEV-56286) A low-molecular-weight drug candidate (oligomer modulator) that specifically binds to toxic oligomer structures of alpha-synuclein, dissolves toxic oligomers, and prevents formation of new oligomers. Can be administered orally and efficiently crosses the blood-brain barrier to act directly intracellularly on toxic oligomers. Developed for Multiple System Atrophy (MSA) and Parkinson's disease in partnership with Teva Pharmaceutical, with FDA Fast Track and Orphan Drug Designations. Currently in Phase 2 clinical study with 200 study participants.
  • PET Tracer Program Novel PET tracer compounds that specifically target aggregated alpha-synuclein, enabling direct molecular imaging and quantification of alpha-synuclein deposits in patients' brains for the first time. First tracer candidates have been explored in human PET images in patients with MSA and Parkinson's disease, showing promising preliminary results. Developed in collaboration with University of Tübingen, Max Planck Institute for Multidisciplinary Sciences, and LMU Munich.

Quantifiable outcome

  • PD DETECT sensitivity: 97.8%
  • +2 more outcomes

Companies that use Modag

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles3 records

Modag technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Modag partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, major and minor.

  • Teva Pharmaceutical Industries Ltd.coreStrategic or Co-development Partner · 26 October 2021Exclusive worldwide licensing and development collaboration for Anle138b (Emrusolmin) and Sery433. Teva received exclusive rights to develop, manufacture, and commercialize these compounds. Both companies jointly develop the drugs for MSA and Parkinson's disease indications, with potential for additional indications based on clinical outcomes. The partnership leverages Teva's neuroscience expertise and global commercial infrastructure.
  • University of TübingenmajorStrategic or Co-development PartnerAcademic partner in PET tracer program development, contributing to molecular imaging research for synucleinopathies.
  • Max Planck Institute for Multidisciplinary Sciences, GöttingenmajorStrategic or Co-development PartnerAcademic research partner contributing to PET tracer development and alpha-synuclein research. Foundation partner in company's scientific origins.
  • Ludwig-Maximilians-University MunichmajorStrategic or Co-development PartnerAcademic partner in PET tracer research and fundamental research origin of MODAG's technology platform. Company was founded based on discoveries from LMU scientists.
  • Quotient SciencesminorStrategic or Co-development PartnerContract research organization that conducted the Phase 1b study for anle138b in Parkinson's patients in collaboration with University Hospital Nottingham.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Modag competitors and assessment

Company assessment

Direct peers

  • Prothena (Roche partner): Prothena, partnered with Roche, is developing prasinezumab, a monoclonal antibody targeting aggregated alpha-synuclein for Parkinson's disease. It is the most direct mechanistic competitor to MODAG's Emrusolmin in the synucleinopathy space.
  • AC Immune: AC Immune is a clinical-stage Swiss biotech developing alpha-synuclein-targeted therapeutics and diagnostics for Parkinson's and related synucleinopathies. It is closely comparable as a European, CNS-focused, alpha-synuclein platform company.
  • Amprion: Amprion develops SYNTap, a seed amplification assay for misfolded alpha-synuclein used in Parkinson's diagnosis and clinical research. It is a direct competitor to MODAG's PD DETECT diagnostic kit and is widely used in academic and pharma studies.

Broad incumbents

  • Biogen: Biogen developed cinpanemab, an alpha-synuclein antibody for Parkinson's, and has a broad neuroscience portfolio. As a large CNS player pursuing the same target, Biogen is a direct mechanistic and indication peer even though MODAG is far smaller.
  • Lundbeck: Lundbeck is a Denmark-based specialty pharmaceutical company focused on CNS disorders including Parkinson's disease. It competes for the same patient population and physician channels that MODAG's therapeutic and diagnostic programs target.
  • UCB: UCB is a global biopharma company with a growing neuroscience portfolio including Parkinson's disease programs. It is comparable as a CNS-focused commercial-stage peer whose indication overlap puts it in direct competition for future launch slots.

Emerging players

  • Denali Therapeutics: Denali is a clinical-stage neurodegeneration biotech developing small molecules and biologics for Parkinson's and related diseases, including programs that intersect with alpha-synuclein biology. It is a peer in CNS drug development with broader neurodegeneration scope.
  • BioArctic: BioArctic is a Swedish biotech developing alpha-synuclein PET tracers and antibody-based therapies for Parkinson's disease. The PET tracer program is a direct peer to MODAG's PET tracer initiative, while their antibody work is mechanistically adjacent.
  • Cerevel Therapeutics (AbbVie): Cerevel, now part of AbbVie, is developing CNS therapeutics including assets for Parkinson's disease. It is an emerging peer in the disease-modifying Parkinson's space, with similar neuroscience specialization to MODAG's therapeutic ambition.

Others

  • Quotient Sciences: Quotient Sciences is the contract research organization that conducted MODAG's Phase 1b anle138b study in Parkinson's patients. It is an enabling/operational peer in MODAG's drug development workflow rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Modag social profiles

Digital presence

Modag compliance and trust

Trust signal

Compliance1 record

Modag financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Modag leadership team

Management profile

Number of profiles

Profiles3 records

Modag funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Modag M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Modag

What does Modag do?

MODAG develops and commercializes disease-modifying small-molecule therapeutics (Emrusolmin/anle138b) and companion biochemical diagnostics (PD DETECT) targeting pathological alpha-synuclein aggregates in neurodegenerative diseases, specifically Parkinson's disease and Multiple System Atrophy (MSA). The company combines proprietary oligomer modulator chemistry with the world's first CE-IVDR-certified seed amplification assay for Parkinson's diagnosis and is developing PET tracers for molecular imaging of synucleinopathies.

Is Modag a public or private company?

Modag is a private company. It is classified as venture growth investor backed and is currently operating.

When was Modag founded?

Modag was founded in 2013. It employs 11 to 50 people.

Where is Modag based?

Modag is headquartered in Wendelsheim, Germany, in the Europe region.

How does Modag make money?

Three revenue lines are on record. Diagnostic Products are the primary driver. The others are licensing and Collaboration Revenue and research Grants.

Who are Modag's main competitors?

Direct peers on record are Prothena (Roche partner), AC Immune and Amprion. Broad incumbents are Biogen, Lundbeck and UCB. Emerging players are Denali Therapeutics, BioArctic and Cerevel Therapeutics (AbbVie). Quotient Sciences is listed as an others.

Does Modag have an API?

No public API is recorded for Modag.

What industry is Modag in?

Modag's product category is Biopharmaceuticals and Diagnostics for Neurodegenerative Diseases. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PMLiVECPHI Pharma Awards 2026 winners announced in MilanThe CPHI Pharma Awards 2026 winners were announced on 6 October in Milan, recognizing companies and individuals across 15 categories. The awards, sponsored by MOEA, Taiwan Pharmaceutical Alliance, and IQVIA, covered areas such as drug delivery, digital transformation, and sustainability. Winners include MODAG, Evonik, and others.Longevity.TechnologyMODAG brings world’s first Parkinson’s test to marketGerman biotech company MODAG has launched PD DETECT, the world's first CE-certified biochemical standardized test kit for Parkinson's disease, designed to detect abnormal alpha-synuclein protein aggregates in cerebrospinal fluid for earlier and more objective diagnosis. The test reportedly delivers a sensitivity of 97.8% and specificity of 100%, distinguishing Parkinson's from other neurodegenerative conditions that can present similarly in clinical settings. The product is now available to specialized diagnostic laboratories, university clinics, and research institutions, representing a shift from diagnosing Parkinson\u2019s through visible symptoms to identifying the underlying biology before motor symptoms fully manifest.Business Wire BlogRhineland-Palatinate Biotech Company MODAG Receives Research Grant Funding from The Michael J. Fox FoundationMODAG GmbH, a German biotechnology company, announced it has received a $1 million research grant from The Michael J. Fox Foundation for Parkinson's Research to advance its PET tracer programs targeting aggregated alpha-synuclein for earlier Parkinson's disease detection. The tracers enable visualization and quantification of alpha-synuclein deposits in patients for the first time, representing a potential breakthrough in neurodegenerative disease diagnostics. MODAG is implementing the program in cooperation with academic partners including the University of Tübingen, Max Planck Institute, and Ludwig-Maximilians-University.PharmiWeb.comRhineland-Palatinate Biotech Company MODAG Receives Research Grant Funding from The Michael J. Fox FoundationMODAG GmbH received a $1 million research grant from The Michael J. Fox Foundation to advance its PET tracer programs for Parkinson's disease detection. The funding will support the development of novel tracers targeting alpha-synuclein aggregates, key features of neurodegenerative diseases, enabling earlier diagnosis and therapy development.GlobeNewswireTeva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System AtrophyTeva received FDA Fast Track designation for emrusolmin (TEV-56286), an investigational therapy for Multiple System Atrophy, in Phase 2 development. The drug targets alpha-synuclein and is part of a collaboration with MODAG GmbH. The designation aims to expedite review of this treatment for the rare neurodegenerative disorder.BenzingaTeva Q3 Earnings Fall Short Of Expectations; Reaffirms FY21 Guidance - Teva Pharmaceutical Indus (NYSE:TETeva Pharmaceutical Industries reported Q3 sales of $3.89 billion, missing the consensus estimate of $4.03 billion, primarily due to lower revenues from Copaxone and generic products in North America. The company reaffirmed its full-year revenue guidance of $16–$16.4 billion while announcing a collaboration with MODAG GmbH for neurodegenerative disease compounds and plans to issue $3.5 billion in sustainability-linked notes.FierceBiotechModag raises series A round to test disease-modifying parkinsonian disorders drugModag raised €12 million in a series A round led by Massa Investment to take its drug anle138b into the clinic for multiple system atrophy. The drug targets alpha-synuclein oligomers and has shown promise in preclinical models. The company plans to generate proof of concept, with potential relevance to Parkinson's and dementia with Lewy bodies.